VEGFR2
Chinese Trial Suggests PARP, VEGF Inhibitor Combo Benefits Advanced BRCA1/2-Mutant Breast Cancer
Premium
Fuzuloparib, both alone and combined with apatinib, improved patients' progression-free survival versus standard chemotherapy.
Failed Trial Suggests Circulating Tumor DNA Monitoring Not as Universally Applicable as Hoped
Premium
Investigators stressed that their results don't mean that ctDNA monitoring shouldn't be pursued in advanced cancer settings but that they offer a cautionary tale.
Exploratory Study Finds Genomic Markers of Response to Tecentriq, Avastin in Advanced Liver Cancer
Several genomic markers were associated with improved progression-free survival among patients treated with Tecentriq and Avastin versus Tecentriq alone.